What is Sunitix 12.5mg Sunitinib?
Sunitix medicine contains the active ingredient Sunitinib, which is used for the treatment of cancers such as advanced kidney cancer, gastrointestinal stromal tumors (GISTs) and pancreatic neuroendocrine tumors.
The drug works by blocking the action of certain enzymes that are involved in the growth of cancer cells. Sunitinib is classified as a protein kinase inhibitor.
Drug information Sunitix 12.5mg for the treatment of kidney, intestinal and pancreatic cancer
- Brand Name: Sunitix.
- Active ingredient: Sunitinib.
- Manufacturer: Beacon.
- Content: 12.5mg
- Form: Capsules.
- Packaging: 1 box of 28 tablets.
Sunitinib’s mechanism of action
Sunitinib inhibits cell signaling by targeting multiple receptor tyrosine kinases (RTKs).
These include all platelet-derived growth factor receptors (PDGF-Rs) and vascular endothelial growth factor receptors (VEGFRs), which play a role in both angiogenesis tumor and tumor cell proliferation.
Simultaneous inhibition of these targets thus reduces tumor vascularity and activates cancer cell apoptosis and thus leads to tumor shrinkage.
Sunitinib also inhibits CD117 (c-KIT), the receptor tyrosine kinase that (when improperly activated by mutation) drives the majority of gastrointestinal stromal cell tumors. It has been suggested as a second-line therapy for patients whose tumors have developed mutations in c-KIT that make them resistant to imatinib or who cannot tolerate the drug.
Indications for treatment of the drug Sunitix
Blocks gastrointestinal stromal tumor (GIST) : the drug is indicated for the treatment blocks gastrointestinal stromal tumor malignant inoperable or metastatic (GIST) in adults after treatment Imatinib failure due to drug resistance or intolerant.
Metastatic renal cell carcinoma (MRCC): indicated for the treatment of metastatic renal cell carcinoma (MRCC) in adults.
Pancreatic neuroendocrine tumors (pNET): indicated for the treatment of unresectable or metastatic well-differentiated pancreatic neuroendocrine tumors (pNETs) with disease progression in adults.
Contraindications to the use of Sunitix
- Do not use the drug for people who are sensitive to Sunitinib or any of its ingredients.
- Not for use by pregnant and lactating women (unless otherwise indicated).
Dosage of Sunitix
Treatment of gastrointestinal stromal tumor (GIST) after disease progression or intolerance to imatinib mesylate. 50 mg/day for 4 weeks, then 2 weeks off for a 6-week cycle.
FFTreatment of advanced renal cell carcinoma (RCC). 50 mg/day for 4 weeks, then 2 weeks off for a 6-week cycle.
Adjuvant treatment of adult patients at high risk of recurrent RCC after nephrectomy. 50 mg/day for 4 weeks, then 2 weeks off for a 6-week cycle.
Treatment of advanced, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease. 37.5 mg/day continuously without scheduled treatment time.
How to use Sunitix
- Sunitix can be taken with or without food, swallowing the capsule whole.
- Use only as directed by your doctor. Do not increase or decrease this dose unless advised to do so.
- Should be taken at the same time of day for maximum effectiveness
What to do in case of overdose?
- Call 911 immediately or go to the nearest local health station.
- Of course, you’ll need to keep a record and bring a list of all the medications you’ve taken, including prescription and over-the-counter drugs.
What should I do if I miss a dose?
- If you forget to take a dose, take it as soon as possible.
- But if it is almost time for your next dose, skip the missed dose and take your next dose at the scheduled time.
- Do not take double the prescribed dose.
Sunitix side effects
Common side effects of Sunitix include:
- Indigestion, loss of appetite, stomach pain, nausea, vomiting, diarrhea;
- Feeling weak or tired, weak
- Blisters or ulcers in the mouth, red or swollen gums, change in taste, trouble swallowing;
- Blisters or rash on hands or feet;
- Bruising or bleeding.
- Skin rash, skin or hair color change, mucositis.
Rare dangerous side effects with use: Hives, difficulty breathing, swelling of the face or throat, or severe skin reaction (fever, sore throat, burning in eyes, skin pain, red or purple rash). skin spreads and causes blistering and peeling).
Any warnings when using Sunitix?
Before you start taking Sunitix Capsules, talk to your doctor and tell them all the medicines you are taking. Also make sure they know about your complete medical history.
Sunitix may slow wound healing. Avoid any form of surgery while taking the medication. If surgery is unavoidable, tell your healthcare provider that you are taking Sunitix.
Do not give live vaccines to patients receiving Sunitix.
For pregnant & lactating women
Pregnancy: Pregnant women should not use Sunitix because it will cause reproductive toxicity including birth defects.
Lactation: Sunitinib is metabolized and excreted in breast milk and has the potential to cause serious adverse reactions in nursing infants. Women should not breast-feed while taking this medicine.
Drug interactions with Sunitix 12.5mg Sunitinib
Effect of CYP3A4 . inhibitors
In healthy volunteers, co-administration of a single dose with a strong CYP3A4 inhibitor ketoconazole resulted in an increase in the combined maximum [sunitinib + major metabolite] concentrations (C max) and AUC values. curvature (AUC 0-∞ ) of 49% and 51%, respectively.
Using the drug with strong CYP3A4 inhibitors (eg, ritonavir, itraconazole, erythromycin , clarithromycin , grapefruit juice) may increase the concentration of the active substance.
Therefore, the combination with CYP3A4 inhibitors should be avoided, or an alternative medicinal product with no or minimal CYP3A4 inhibitory potential should be considered.
If this is not possible, the dose of Sutent may need to be reduced to a minimum of 37.5 mg daily for GIST and MRCC or 25 mg daily for pNET, based on careful monitoring of tolerability (see section 4.2).
The effect of breast cancer resistance protein (BCRP) inhibitors
Limited clinical data are available on interactions between sunitinib and BCRP inhibitors and the possibility of an interaction between sunitinib and other BCRP inhibitors cannot be excluded.
Effect of CYP3A4 . inducers
In healthy volunteers, co-administration of a single dose of sunitinib with the CYP3A4 inducer rifampicin resulted in a 23% and 46% reduction in combined Cmax and AUC 0-∞ values, respectively.
How much does Sunitix cost?
How much is the price of Sunitix 12.5mg? Please COMMENT below or Contact 0933049874 (Zalo/ Facebook/ Viber/ Whatsapp) to buy and sell brand-name drugs in Ho Chi Minh City, Hanoi, Da Nang City, Can Tho City,… nationwide.
How to store Sunitix?
- You should store the medicine at room temperature, in a cool, dry place, away from direct sunlight.
- You should not store the medicine in the refrigerator.
- Keep the medicine out of the reach of children.
- Do not throw medicine down the toilet or plumbing.
The above article is for reference only and is not a substitute for medical diagnosis or treatment. Readers should only follow the instructions of the doctor who is treating you, Index-china disclaims responsibility if problems occur.
Reputable source ThuocLP Vietnamese: Sunitix medicine 50mg Sunitinib treatment of kidney cancer
Assoc.Prof.Dr. Tran Ngoc Anh is currently Hanoi Medical University Hospital, Associate Professor, Department of Internal Medicine, Gastroenterology and Head of Department of General-Uematology of Hanoi Medical University. Consulting doctor at ThuocLP Pharmacy.
Professional qualifications, Academic degrees – Education:
Graduated from General Practitioner System, Hanoi Medical University
Graduated with a Master degree in Internal Medicine, Hanoi Medical University
Graduated from the training program specialized in Gastrointestinal, Henri Mondor Institute Center, University of Paris 6, French Republic 1996-1997; 1999
Graduated from the training program specialized in Gastrointestinal, North Royal Sydney Hospital, Australia; 2002
Graduated from a training program specialized in chronic liver diseases, Pizza, Italy 2009
Graduated with a PhD in Gastrointestinal, Hanoi Medical University
Associate Professor, Gastroenterology, Hanoi Medical University
Training and Scientific Research:
Published more than 200 articles in domestic and international specialized journals
Editor of many monographs and participates in compiling 2 textbooks.
Guide many students and graduate students of Hanoi Medical University
Manager of many grassroots research projects
Certificate of Good Clinical Practice (GCP: 2012, 2015), Ministry of Health
Specialized certificates: General gastrointestinal endoscopy, Interventional gastrointestinal endoscopy, General gastrointestinal ultrasound, Interventional gastrointestinal ultrasound (Bach Mai BV), Chronic liver disease.